Research location
Bergisch Gladbach
North Rhine-Westphalia, Germany
Advertisement
Research activity in Bergisch Gladbach
North Rhine-Westphalia, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 18 trials and 18 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bergisch Gladbach
18 linked trials · page 1 of 1A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · 2023-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerNCT05587296 · 2022-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCNCT04565054 · 2020-09-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNCT04055493 · 2019-07-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D MammographyNCT03377036 · 2018-07-05 · 1 site observation
ACTIVE_NOT_RECRUITING
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignNCT03467425 · 2018-04-11 · 1 site observation
COMPLETED
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383 · 2017-10-09 · 1 site observation
COMPLETED
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03034915 · 2017-06-16 · 1 site observation
COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02164513 · 2014-06-30 · 1 site observation
COMPLETED
Dimethyl Fumarate (DMF) Observational StudyNCT02047097 · 2013-11-19 · 1 site observation
COMPLETED
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.NCT01475721 · 2011-11-18 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate AlzheimersNCT00490568 · 2007-08-08 · 1 site observation
TERMINATED
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseNCT00348309 · 2006-07-06 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.